Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · Real-Time Price · USD

4.130

+0.050 (1.23%)

At close: Oct 22, 2026, 4:00 PM EDT

4.030

-0.100 (-2.42%)

Pre-market: Oct 23, 2026, 4:10 AM EDT

Aquestive Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	54.09	44.55	57.56	50.58	47.68	50.83
Revenue Growth	22.56%	-22.61%	13.79%	6.09%	-6.20%	10.87%
Cost of Revenue	17.83	18.56	17.87	20.83	19.39	14.99
Gross Profit	36.26	25.99	39.69	29.75	28.29	35.84
Selling, General & Admin	73.11	79.85	50.18	31.75	52.88	53.48
Research & Development	15.89	17.19	20.28	13.1	17.48	17.05
Operating Expenses	89	97.04	70.46	44.85	70.36	70.52
Operating Income	-52.75	-71.05	-30.77	-15.1	-42.07	-34.68
Interest Expense	-16.32	-17.1	-16.82	-7.46	-12.44	-22.46
Interest & Investment Income	2.52	4.37	3.14	1.82	0.1	0.42
Other Non Operating Income (Expenses)	-	-	-	6	-	-
EBT Excluding Unusual Items	-66.54	-83.78	-44.45	-14.74	-54.41	-56.72
Legal Settlements	-	-	-	8.5	-	-
Other Unusual Items	-11.68	-	0.3	-1.38	-	-13.82
Pretax Income	-78.23	-83.78	-44.15	-7.63	-54.41	-70.54
Income Tax Expense	-	-	-0.01	0.25	-	-
Net Income	-78.23	-83.78	-44.14	-7.87	-54.41	-70.54
Net Income to Common	-78.23	-83.78	-44.14	-7.87	-54.41	-70.54
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	120	107	87	61	49	38
Shares Outstanding (Diluted)	120	107	87	61	49	38
Shares Change	27.37%	23.29%	41.58%	25.69%	27.99%	13.15%
EPS (Basic)	-0.65	-0.78	-0.51	-0.13	-1.12	-1.85
EPS (Diluted)	-0.65	-0.78	-0.51	-0.13	-1.12	-1.85
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-45.95	-52.99	-35.92	-7.38	-10.84	-33.89
Free Cash Flow Per Share	-0.38	-0.50	-0.41	-0.12	-0.22	-0.89
Gross Margin	67.04%	58.34%	68.95%	58.82%	59.34%	70.51%
Operating Margin	-97.52%	-159.50%	-53.46%	-29.86%	-88.23%	-68.22%
Profit Margin	-144.63%	-188.09%	-76.68%	-15.56%	-114.12%	-138.77%
Free Cash Flow Margin	-84.95%	-118.97%	-62.40%	-14.58%	-22.74%	-66.67%
EBITDA	-52.2	-70.48	-30.03	-13.73	-39.51	-31.53
EBITDA Margin	-96.51%	-158.22%	-52.17%	-27.14%	-82.87%	-62.02%
D&A For EBITDA	0.54	0.57	0.74	1.37	2.55	3.15
EBIT	-52.75	-71.05	-30.77	-15.1	-42.07	-34.68
EBIT Margin	-97.52%	-159.50%	-53.46%	-29.86%	-88.23%	-68.22%

SEC Filings: 10-K · 10-Q